The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.
Open accessAbstract
Background Long-term maintenance of weight loss remains a therapeutic challenge in obesity treatment.Objective This multicenter, double-blind, placebo-controlled study was designed to test the hypothesis that orlistat, a gastrointestinal lipase inhibitor, is significantly more effective than a placebo in preventing weight regain.Design Obese subjects who lost > or = 8% of their initial body weight during a 6-mo lead-in of a prescribed hypoenergetic diet (4180-kJ/d deficit) with no adjunctive pharmacotherapy were randomly assigned to receive placebo, 30 mg orlistat, 60 mg orlistat, or 120 mg orlistat 3 times daily for 1 y in combination with a maintenance diet to help prevent weight regain. Of 1313 recruited subjects [body mass index (in kg/m2): 28-43], 729 subjects lost > or =8% of their initial body weight during the 6-mo weight-loss lead-in period and were enrolled in the double-blind phase.Results After 1 y, subjects treated with 120 mg orlistat 3 times daily regained less weight than did placebo-treated subjects (32.8 +/- 4.5% compared with 58.7 +/- 5.8% regain of lost weight; P < 0.001). Moreover, more subjects in the 120-mg orlistat group than in the placebo group regained < or = 25% of lost weight (47.5% of subjects compared with 29.9%). In addition, orlistat treatment (120 mg 3 times daily) was associated with significantly greater reductions in total and LDL-cholesterol concentrations than was placebo (P < 0.001).Conclusion The use of orlistat during periods of attempted weight maintenance minimizes weight readjustment and facilitates long-term improvement in obesity-related disease risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“There is also evidence that antiobesity medications, including long-acting glucagon-like peptide-1 (GLP-1) receptor agonists, naltrexone/bupropion, phentermine/topiramate, and orlistat, may help maintenance of achieved weight reduction.5,7,8,9,10,11,12”
From Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial (2024) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical principles in experimental design.
Winer, B. J. (1962) · McGraw-Hill Book Company · doi:10.1037/11774-000 · Cited by 27,137
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,453
Overweight and obesity in the United States: prevalence and trends, 1960–1994
Flegal, K., Carroll, M., Kuczmarski, R., & Johnson, C. (1998) · International Journal of Obesity · doi:10.1038/sj.ijo.0800541 · Cited by 3,045
Energy and protein requirements*
Pacey, A., & Payne, P. (2019) · Routledge eBooks · doi:10.4324/9780429036279-4 · Cited by 2,545
Changes in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012
Statistical Principles in Experimental Design.
Geisser, S., & Winer, B. J. (1963) · Journal of the American Statistical Association · doi:10.2307/2283359 · Cited by 1,934
(1998) · PubMed · Cited by 1,259
Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Beneficial health effects of modest weight loss.
Goldstein, D. J. (1992) · PubMed · Cited by 915
American Heart Association Call to Action: Obesity as a Major Risk Factor for Coronary Heart Disease
Eckel, R. H., & Krauss, R. M. (1998) · Circulation · doi:10.1161/01.cir.97.21.2099 · Cited by 807
Research works printed but not linked: 1
- 1985, Energy and protein requirement. Report of a joint FAO/WHO/UNU Expert Consultation, World Health Organ Tech Rep Ser, 724
Cited by
Sorted by citations
Items 201–289 of 289
Linne, Y. M., Rooth, P., & Rössner, S. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802401 · Cited by 7
The impact of education on weight loss in overweight and obese adults.
Ostovan, M. A., Zibaeenezhad, M. J., Keshmiri, H., & Shekarforoush, S. (2013) · Europe PMC (PubMed Central) · Cited by 7
Ghoreishy, S. M., Noormohammadi, M., Zeraattalab-Motlagh, S., Shoaibinobarian, N., Rashedi, M. H., Movahed, S., Hemmati, A., Nazarian, A., Fernandez, M. L., & Shidfar, F. (2024) · Nutrition Reviews · doi:10.1093/nutrit/nuae128 · Cited by 6
Clinical Guidelines of Treatment of Obesity in Adults
Park, Y.-W. (2003) · Journal of the Korean Medical Association · doi:10.5124/jkma.2003.46.4.345 · Cited by 6
“729 명의 비만 환자를 대상으로 6개월간의 저열량식으로 8% 체중감량 후 orlistat을 복용하게 하여 감량체중 유지효 과를 본 연구에서 1일 360 mg 복용군은 33%의 체중 재 증가를 보여 59%의 위약군에 비해 유의하게 낮은 수치 를 보였다(41).”
Pancreatic Lipase Inhibitory Phthalide Derivatives from the Rhizome of Cnidium officinale
Mo, E. J., Jo, Y. H., Jeong, J. Y., Kim, S. B., Liu, Q., Hwang, B. Y., & Lee, M. K. (2016) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 6
Obesity: Overview of Treatments and Interventions
SEAGLE, H. M., WYATT, H., & Hill, J. O. (2001) · Elsevier eBooks · doi:10.1016/b978-012193155-1/50033-7 · Cited by 6
Self-citationTratamiento farmacológico de la obesidad: presente, pasado y futuro
Valdelamar, L., Rodríguez, M., Bermúdez, V., Leal, E., Bermúdez, F., Cabrera, M., Mengual, E., Silva, C., Amell, A., & Toledo, A. (2007) · Archivos Venezolanos de Farmacología y Terapéutica · Cited by 5
Quiroz-Eraso, S., Rodríguez-Castaño, G. P., & Acosta‐González, A. (2023) · Current Research in Food Science · doi:10.1016/j.crfs.2023.100594 · Cited by 5
“This drug is a lipase inhibitor that prevents lipid hydrolysis and reduces fat absorption by up to 30% (Hill et al., 1999; Yanovski and Yanovski, 2014).”
BackgroundThe Suppressive Effect of Protamine from Chum Salmon Milt on Lipid Absorption in Humans
Hoshino, Y., Takahashi, Y., Kawarasaki, M., Akita, R., Enari, H., & Yamamoto, S. (2008) · NIPPON SHOKUHIN KOGYO GAKKAISHI · doi:10.3136/nskkk.55.360 · Cited by 5
Kim, E. S., Lee, K. J., Oh, K. H., Ahn, J. H., Kim, S. B., Liu, Q., Hwang, B. Y., & Lee, M. K. (2012) · Natural Product Sciences · Cited by 5
Suppressive Effect of Polyphenols Extracted from Chestnut Skins on Lipid Absorption in Rats
Kawasaki, K., Shiromizu, T., & Katsui, M. (2009) · NIPPON SHOKUHIN KOGYO GAKKAISHI · doi:10.3136/nskkk.56.545 · Cited by 5
Recent and Future Drugs for the Treatment of Obesity
Gaal, L. F. V., Mertens, I. L., & Leeuw, I. H. D. (2001) · doi:10.1002/0470846739.ch31 · Cited by 5
Recent progress in obesity pharmacotherapy
Ryan, D. H. (2000) · Current Opinion in Gastroenterology · doi:10.1097/00001574-200003000-00012 · Cited by 5
Barazzoni, R., Monami, M., Buscemi, S., Busetto, L., Luca, M. D., Navarra, G., Ragghianti, B., Silverii, G. A., Belluzzi, A., Mannucci, E., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70204 · Cited by 5
Pharmacological Management of Obesity
Bray, G. A. (2005) · KARGER eBooks · doi:10.1159/000084358 · Cited by 4
Pattern of Orlistat Exposures in Children Aged 5 Years Or Less
Forrester, M. B. (2008) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2007.10.052 · Cited by 4
Czernichow, S., Knol, M. J., Fezeu, L., & Grobbee, D. E. (2011) · European Journal of Preventive Cardiology · doi:10.1177/1741826711406058 · Cited by 4
“Subsequent randomized trials have shown orlistat to have similar efficacy in weight reduction,(19,20) and maintenance.(21,22) Weight reduction with orlistat appeared to be associated with a favourable effect on various cardiovascular risk factors.”
BackgroundPlock, N., Bax, L., Lee, D., DeManno, D. A., Lahu, G., & Pfister, M. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.781 · Cited by 4
Review-Novel synthetic curcuminoids: Not merely an anticancer agent.
Zhang, H., Jiang, X., Song, W., & Yang, Z. (2019) · PubMed · Cited by 4
Park, M.-Y., Lee, H. J., Choi, D. H., Kang, B.-J., Choi, S., & Park, Y. S. (2017) · Toxicology and Environmental Health Sciences · doi:10.1007/s13530-017-0336-y · Cited by 3
Spotlight on Orlistat in the Management of Patients with Obesity1
Curran, M. P., & Scott, L. J. (2005) · Treatments in Endocrinology · doi:10.2165/00024677-200504020-00006 · Cited by 3
Dunican, K. C., Desilets, A. R., & DeBellis, R. J. (2007) · American Journal of Lifestyle Medicine · doi:10.1177/1559827607303256 · Cited by 3
Inhibitors of absorption as anti-obesity drugs.
Tsuji, M., SAITO, N., & Inoue, S. (2001) · Folia Pharmacologica Japonica · doi:10.1254/fpj.118.340 · Cited by 3
Rodríguez–Jiménez, R., Martinez, M. J., Bernal, L., Pelegrín, L., Franco, S., & Oliva, R. R. (2005) · Cited by 3
Long‐Term Medication Use and Weight Loss Maintenance: An Observational Study
Womble, L. G., Wadden, T. A., Berkowitz, R. I., Sarwer, D. B., & Rothman, R. A. (2001) · Obesity Research · doi:10.1038/oby.2001.88 · Cited by 3
Corsica, J. A., & Perri, M. G. (2003) · Wiley eBooks · doi:10.1002/0471264385.wei0906 · Cited by 3
The Obesity Drug Revolution: New Frontiers in Pharmacotherapy
Manoria, P. C. (2025) · Cureus · doi:10.7759/cureus.96713 · Cited by 2
“A U.S. trial showed 32.8% regain vs. 58.7% in placebo (P 0.001) after diet-induced weight loss, confirming its benefit in maintenance [20].”
InfluentialAbdelfattah, M. S., Fouad, M. A., El-Ahmady, S. H., & Farag, M. A. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118363 · Cited by 2
McCarthy, W. J. (2000) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.3.846a · Cited by 2
“Hill et al’s Figure 3 appears to show that the orlistat group decreased their dietary fat intake 5-fold more than did the placebo group, from week 2 of orlistat therapy to 1 y of follow-up.”
BackgroundMethodInfluentialBehavior therapy and Sibutramine for the treatment of adolescent obesity.
Berkowitz, R. I., Wadden, T., Tershakovec, A., & Cronquist, J. L. (2005) · Obesity and metabolism · doi:10.14341/2071-8713-4933 · Cited by 2
Invited Review: The Medical Management of Obesity and the Role of Pharmacotherapy: An Update
Apovian, C. M. (2000) · Nutrition in Clinical Practice · doi:10.1177/088453360001500103 · Cited by 2
Weight-reducing drug therapy and hypertension
Schimkus, J., & Scholze, J. (2008) · Therapy · doi:10.2217/14750708.5.6.779 · Cited by 2
Bray, G. A. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-0089-1.50015-7 · Cited by 2
Obesity and binge eating disorder
(2006) · Acta Paediatrica · doi:10.1111/j.1651-2227.2006.tb02245.x · Cited by 2
Drugs That Modify Fat Absorption and Alter Metabolism
Gaal, L. V. (2008) · CRC Press eBooks · doi:10.3109/9781420051452-20 · Cited by 2
Reply to MH Davidson, JW Anderson, EC Konz, and GL Blackburn
Halsted, C. H. (2000) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.3.846 · Cited by 2
Hauner, H. (2004) · CRC Press eBooks · doi:10.1201/9780203508756.pt4 · Cited by 2
Benefits of Lifestyle Modification in the Pharmacologic Treatment of Obesity: A Randomized Trial
Wadden, T. A., Berkowitz, R. I., Sarwer, D. B., Prus-Wisniewski, R., & Steinberg, C. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.2.218 · Cited by 1
INVESTIGATION OF LIPASE INHIBITORY ACTIVITY OF NOVEL PROBIOTICS ISOLATED FROM IRANIAN DAIRY PRODUCTS
Mohkam, M., Afifi, N., Zamir, A. R., Heidari, R., Zamani, M. R., Nezafat, N., & Ghasemi, Y. (2023) · Journal of Microbiology Biotechnology and Food Sciences · doi:10.55251/jmbfs.9357 · Cited by 2
Salim, J., Tandy, S., & Puspitasari, G. (2024) · Mediterranean Journal of Nutrition and Metabolism · doi:10.1177/1973798x241289779 · Cited by 1
Mitropoulou, P., Prokšelj, K., Janež, A., Gil, F. R., Verma, S., Jurić, I., Vida, V. L., Gatzoulis, M. Α., & Brida, M. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag067 · Cited by 2
Chen, Z., Cheng, R., Wang, H., & Hu, F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71083 · Cited by 2
“A pooled analysis of 8 RCTs [24–28, 31, 33, 35], comprising 1932 individuals in the AOM group and 1672 in the placebo group, showed that AOMs were associated with additional significant reductions in TG compared with placebo (WMD: − 13.98 mg/dL, 95% CI: − 23.97 to − 3.98, p = 0.006) (Figure 5A).”
InfluentialBray, G. A. (2005) · Humana Press eBooks · doi:10.1385/1-59259-865-x:241 · Cited by 1
WEIGHT MAINTENANCE FOLLOWING THE COMPLETION OF A WEIGHT LOSS TRIAL: EXPLORING RACIAL DIFFERENCES
Turk, M. T. (2008) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
A New Phenolic Diterpene From the Leaves of Rosmarinus officinalis
Zhang, T., Zhao, D., Li, S., Zhang, K., Yang, M., Huang, X., Li, L., & Ma, Y. (2022) · Natural Product Communications · doi:10.1177/1934578x221075854 · Cited by 1
“As part of our continuous studies on dietary supplements for diabetes, 1 new phenolic diterpene, 7-butoxyrosmanol (1), and 3 known ones (2-4) were isolated from Rosmarinus officinalis.”
BackgroundPharmacologic Treatment of Obesity: Pitfalls and New Promises
Bermúdez, V., Rodríguez, M., Valdelamar, L., Luti, Y., Ciszek, A., Urdaneta, L., Guerra, X., Gotera, D., Colmenares, C., Chacín, M., et al. (2008) · Redalyc (Universidad Autónoma del Estado de México) · Cited by 1
Tratamiento farmacológico de la obesidad
Bray, G. A. (2009) · Elsevier eBooks · doi:10.1016/b978-84-8086-428-2.50010-1 · Cited by 1
Oral treatment of unconjugated hyperbilirubinemia
Hafkamp, A. M. (2006) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 1
Management of Type 2 diabetes mellitus in primary care
McDowell, J. R. (2014) · Enlighten: Theses (The University of Glasgow) · Cited by 1
Understanding and Managing Obesity
Corsica, J. A., & Perri, M. G. (2012) · Handbook of Psychology, Second Edition · doi:10.1002/9781118133880.hop209006 · Cited by 1
Benefits and risks of antiobesity agents
Anderson, J. W., & Konz, E. C. (2000) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.3.844a · Cited by 1
Self-citationTratamiento de la obesidad mórbida. Revisión de la evidencia
Canalda, M. I. G., & Villanueva, J. P. C. (2003) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(03)75838-1 · Cited by 1
Neuropharmacology of obstructive sleep apnea and central apnea
Buchanan, P. R., & Grunstein, R. R. (2006) · Birkhäuser-Verlag eBooks · doi:10.1007/3-7643-7440-3_3 · Cited by 1
Efficacy of antiobesity therapies
Davidson, M. H. (2000) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.3.844 · Cited by 1
Sriwisit, S. (2013) · Nottingham ePrints (University of Nottingham)
Hill, J. O., & Aronne, L. J. (2000) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.3.847
Self-citationOverview of the Treatment of Obesity
Freedman, N. S. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-421-6_15
Ahima, R. S. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1607-5_19
Sjöström, L. (2001) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/bf03339768
Review: Pharmacotherapy as part of a weight management programme: a UK perspective
Barnett, A. H. (2007) · The British Journal of Diabetes · doi:10.1177/14746514070070060301
The role of fermentable carbohydrates on appetite regulation in humans
Daud, M. (2012) · Spiral (Imperial College London) · doi:10.25560/14767
“Although its efficacy in reducing body weight has been demonstrated in several studies (Hill et al., 1999; Rossner et al., 2000; Sjostrom et al., 2007), it can cause gastrointestinal side effects such as diarrhoea, flatulence (Padwal et al.”
BackgroundTrujillo, R. C., Acosta, A. D. L., la Parra, M. G.-D., & Tapia, M. G. P. (2010) · Medicina Interna de México
Svendsen, M. N. (2009) · NORA - Norwegian Open Research Archives
Obesidade - Revisão Bibliográfica
da Saúde, C. (2011)
Rutter, P. M., & Newby, D. E. (2012) · Elsevier eBooks · doi:10.1016/b978-0-7295-4079-7.00010-2
Pharmacologic Therapy for Obesity and Overweight in Adults and Adolescents
Aronne, L. J., & Thearle, M. S. (2006) · CRC series in modern nutrition science · doi:10.1201/9781420004649.ch6
Self-citationAdjunctive and Alternative Treatments of Sleep-Related Breathing Disorders
Mulgrew, A. T., Sigurdson, K., & Ayas, N. (2008) · CRC Press eBooks · doi:10.3109/9781420019926-35
Pharmacologic Treatment of Adolescent Obesity
Wadden, T. A., Crerand, C. E., & Berkowitz, R. I. (2006) · CRC Press eBooks · doi:10.1201/9781420019117.sec9
Individual interventions to treat obesity
Townsend, N. P., & Scriven, A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-7020-4634-6.00005-4
Pharmacologic Agents in the Treatment of Obesity
Ryan, D. H. (2006) · Medical psychiatry · doi:10.3109/9780849374517.012
Buranapin, S., & Apovian, C. M. (2006) · Fundamental and clinical cardiology · doi:10.3109/9781420018905.013
Borges, J. G., de Sá, J. A. R., Bezerra, K. S. P., Rolin, L. A., & Almeida, J. R. G. D. S. (2017) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.7198/geintec.v7i1.631
Sharma, A. M. (2002) · doi:10.1002/9780470986882.ch19
Lean, M. E. J., & Campbell, P. T. (2004) · Journal of Drug Evaluation · doi:10.1080/14791130500121412 · Cited by 8
(2011) · CRC Press eBooks · doi:10.1201/b10790-15
(2014) · Elsevier eBooks · doi:10.1016/b978-0-7020-4634-6.09985-4
(2000) · Nutrition in Clinical Practice · doi:10.1177/088453360001500101
(2007) · Springer eBooks · doi:10.1007/0-387-26426-4_6
(2020) · American Academy of PediatricsItasca, IL eBooks · doi:10.1542/9781610023610-33
(2020) · American Academy of PediatricsItasca, IL eBooks · doi:10.1542/9781610024181-33
Use of pharmacotherapy to improve weight loss in early non-responders to behavioral treatmentPreprint
Tronieri, J. S., & Wadden, T. A. (2024) · Research Square · doi:10.21203/rs.3.pex-2526/v1
Hakeem, R., Rashid, T., & Sheikh, M. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22106-4.00004-8
Orlistat: A Gastrointestinal Lipase Inhibitor
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_2
Anti-obesity Pharmacotherapy for Transplant Recipients
Haugen, C. E., & Orandi, B. J. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01388-1 · Cited by 1
BindingDB Entry 50039617: A new pancreatic lipase inhibitor from Broussonetia kanzinoki.
BindingDB (2013) · UC San Diego · doi:10.7270/q2h41sfc
Orlistat and Sibutramine in the Management of Obesity
Wyatt, H. R. (2007) · Springer eBooks · doi:10.1007/978-0-387-32164-6_15
Metadata
- Authors
- Hill, J. O., Hauptman, J., Anderson, J. W., Fujioka, K., O'Neil, P. M., Smith, D. K., Zavoral, J. H., & Aronne, L. J.
- Affiliations
- Scripps Health (US)
- Corresponding author
- Aronne, Louis J
- Venue
- The American Journal of Clinical Nutrition
- Publisher
- Elsevier BV
- Published
- 1999-06
- Volume
- 69
- Issue
- 6
- Pages
- 1108-1116
- ISSN
- 0002-9165 (ISSN-L)
- OpenAlex
- W2166266400
- Cited by
- 287
- References
- 26
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 6 · 2023: 5 · 2022: 3 · 2021: 1 · 2020: 4 · 2019: 2 · 2018: 4 · 2017: 8 · 2016: 5 · 2015: 7 · 2014: 7 · 2013: 6 · 2012: 10
- FWCI
- 14.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- American Journal of Clinical Nutrition (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- orlistat, lipase inhibitors, weight maintenance, weight regain, obesity, hypocaloric diet, long-term weight loss, LDL cholesterol, total cholesterol
- MeSH terms
- Orlistat, Adult, Behavior Therapy, Cardiovascular Diseases, Dietary Fats, Dose-Response Relationship, Drug, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Lactones, Lipase, Cholesterol, HDL, Male, Obesity, Risk Factors, Weight Loss, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
